Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial

On present evidence, in the settings of a developing country, CBRT with concurrent cisplatin cannot be recommended as primary therapy in advanced head and neck cancers without formal comparison with other treatment modalities.